Aspirin is still the first line of therapy for patients with unstable angina or non-ST-elevation myocardial infarction (NSTEMI), and ticagrelor can be used in place of clopidogrel or prasugrel ...

Updated clinical practice guidelines from the American College of Cardiology (ACC) and the American Heart Association (AHA) for the management of patients with unstable angina/non-ST-segment elevation ...

In the unstable angina/NSTEMI group, FFR guidance resulted in an average 1 stent less per patient compared with angiography guidance alone (1.9 ± 1.5 vs. 2.9 ± 1.1; P < 0.01), as well as less contrast ...

By 1 year following ACS, patients with diabetes presenting with UA/NSTEMI had a risk of death that approached patients without diabetes presenting with STEMI (7.2 percent vs. 8.1 percent).

An NSTEMI is diagnosed when your EKG does not show the type of abnormality seen in a STEMI but your blood tests show that your heart is stressed. Unstable angina. This is the least severe type of ACS.

What the quality statement means for different audiences Service providers (cardiac service providers) ensure that local pathways are in place for adults with NSTEMI or unstable angina to be assessed ...

Rationale Coronary angiography is important to define the extent and severity of coronary disease. The benefits of an early invasive strategy appear to be greatest in people at higher risk of future ...

HMG-CoA Reductase Inhibitors Every patient with unstable angina and non-STEMI should receive high-intensity statin therapy, unless contraindicated (Amsterdam EA, et al. J Am Coll Cardiol. 2014;22a).

Aspirin is still the first line of therapy for patients with unstable angina or non-ST-elevation myocardial infarction, and ticagrelor can be used in place of clopidogrel or prasugrel instead of ...

Ticagrelor (Brilinta, AstraZeneca) gains equal standing with prasugrel (Effient, Lilly) and clopdiogrel in the newly released focused update of the ACCF/AHA guidelines for unstable angina and non ...

By 1 year following ACS, patients with diabetes presenting with UA/NSTEMI had a risk of death that approached patients without diabetes presenting with STEMI (7.2 percent vs. 8.1 percent).